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Abstract. Modern radiation therapy is very conformal, resulting in a complexity of delivery that leads to many small 
radiation fields with steep dose gradients, increasing error probability. Quality assurance in delivery of such radiation 
fields is paramount and requires real time and high spatial resolution dosimetry. Semiconductor radiation detectors due to 
their small size, ability to operate in passive and active modes and easy real time multichannel readout satisfy many 
aspects of in vivo and in a phantom quality assurance in modern radiation therapy. Update on the recent developments
and improvements in semiconductor radiation detectors and their application for quality assurance in radiation therapy, 
based mostly on the developments at the Centre for Medical Radiation Physics (CMRP), University of Wollongong, is 
presented.
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INTRODUCTION
Semiconductor detectors can be applied to all fields of radiation medicine, nuclear medicine, radiology and 
radiation therapy. Recently medical imaging technology has benefitted from the application of semiconductor based 
instrumentation developed for High Energy Physics (HEP), such as experiments on the Large Hadron Collider 
(LHC) at CERN. Silicon pixilated detectors, strip detectors and silicon photomultipliers (SiPM) now compete 
effectively with traditional photomultipliers. These devices are used in SPECT, PET, CT, intra-operative imaging 
probes and digital mammography. With the ongoing development of semiconductor radiation detectors and ASIC 
based electronic readout systems, semiconductor based instrumentation for radiation therapy dosimetry is advancing.
This paper will provide an overview of semiconductor radiation detectors for radiation therapy applications, 
including approaches to radiotherapy dosimetry currently under development or in the test phase. Semiconductor 
detectors are well suited to radiation therapy for absorbed dose, dose equivalent and radiobiological efficiency 
(RBE) measurements due to their small size, allowing for excellent spatial resolution, and the potential for real time 
read out. Previous work on nuclear spectroscopy with silicon detectors has translated to silicon microdosimetry and 
its application to dosimetry in neutron therapy, proton therapy and recently, new approaches in mini-dosimetry for 
brachytherapy. 
Another class of semiconductor radiation detectors are based on the measurement of the change in the electrical 
characteristics of the semiconductor due to the introduction of radiation defects or ionization of dielectric layers in 
the device. This kind of detector is suitable for integral dosimetry. One such device is the Metal Oxide 
Semiconductor Field Effect Transistor (MOSFET). This detector has found wide application in conventional 
radiotherapy and recently for synchrotron microbeam radiation therapy (MRT) dosimetry where an excellent spatial 
resolution of the order of a micron or less has been obtained in real time, providing a unique contribution to MRT 
dosimetry.
PIN diodes have been used extensively for conventional photon and charged particle dosimetry via read out in 
ionization mode. While this is the most common mode of operation for PIN diode dosimetry, the diodes can be used 
in both radiation damage and ionization mode simultaneously to measure real time gamma and neutron, or neutron 
and proton dose components in mixed fields, such as fast neutron therapy and proton therapy respectively. The 
advantage being both measurements can be made with the single miniature detector.
Through many years of development and application, dosimetry with silicon radiation detectors has proven to be 
competitive with film dosimetry in regard to spatial resolution, and competitive with dosimetry using array 
ionization chambers in regard to two dimentional  real time dosimetry. Rapidly developing silicon nanotechnology is 
proving promising to the area of microdosimetry with silicon microdosimeters able to substitute the bulky Tissue 
Equivalent Proportional Counters (TEPC) microdosimeters. This is opening a new era of radiobiological quality 
assurance in radiotherapy. 
The purpose of this paper is to provide an update on the recent developments and improvements in 
semiconductor radiation detectors and their application for quality assurance (QA) in radiation therapy, based mostly 
on the developments at the Centre for Medical Radiation Physics (CMRP), University of Wollongong, Australia. As 
well as providing a neat overview, the aim of this paper is to draw attention to the further opportunities that exist for 
silicon radiation detectors in radiotherapy. This paper is a logical extension of previous manuscripts on 
semiconductor dosimetry in radiation therapy presented at the Solid State Dosimetry (SSD) Summer Schools in 
Athens and Yale University [1,2] and should be read in conjunction with these two manuscripts. 
INTEGRAL DIODE SEMICONDUCTOR DOSIMETRY IN RADIATION THERAPY
Conventional radiation therapy involves treating the tumor volume with either photons or electrons produced 
using medical LINACs or, as in brachytherapy, radio-isotopic sources. The accuracy required in delivering the dose 
to the target is usually within 2-3% [3]. Modern radiation therapy techniques, such as Intensity Modulated Radiation 
Therapy (IMRT), involve ‘painting’ the tumor volume with photons to provide a highly conformal dose with steep 
dose gradients. For such treatments a high spatial resolution is required for phantom dosimetry studies. Another 
challenging task in radiation therapy dosimetry is verifying the skin dose in breast, and head and neck treatments. 
Verification requires dosimetry at the depth of the epithelial layer of skin, i.e. about 0.07-1 mm, this limits the 
choice of detector suitable for such a measurement as packaging becomes a key issue. Real time dose verification for 
image guided radiotherapy (IGRT) is another important area that needs to be addressed to establish the appropriate 
QA. Semiconductor dosimeters are well suited to address these areas due to the following advantages they possess:
 A much higher sensitivity compared to an ionization chamber (IC) of the same volume 
(18000 times increase) due to a higher density and a smaller ionization energy compared to 
gas.
 A small dosimetric volume that satisfies the Bragg-Gray cavity theory in most practical 
circumstances, leading to high spatial resolution and the ability to place the detector within 
a confined space in the body and/or phantom.
 The possibility to operate the detector in passive mode (similar to TLDs) or on-line active 
mode (similar to ICs).
The three main semiconductor detectors to be considered in this section are silicon diodes, MOSFET detectors 
and diamond detectors. The first two detectors have the advantage that the silicon to water mass collision stopping 
power ratio is almost energy independent in the MV range typical of conventional photon and electron therapy. This 
leads to near tissue equivalency of the detector for MV radiation therapy dosimetry applications. A further advantage 
of using a silicon based detectors is that for very small sensitive volumes, such as the MOSFET detector (thickness 
<1m), and for particular medical radiation sources, the Bragg-Gray cavity theory is satisfied down to photon 
sources of energy just tens of keV, making these detectors useful down to the KV range of photon dosimetry. When 
the range of the secondary electrons is less than the size of the dosimetric sensitive volume, the mass absorption 
coefficient ratio can become important, resulting in energy response of the dosimeters. Diamond detectors have the 
inherent advantage that the Z of diamond is 6, nearly matching the Z of muscle (7.2), leading to excellent tissue 
equivalency of the detector.
Most radiation semiconductor detectors are p-n junctions. p-n junction theory is well known and can be found in 
[4]. An advantage of the p-n junction is the inbuilt electrical field that exists at the boundary between the  p-type and 
n-type silicon regions . The charge produced by ionizing radiation within the bulk of the material can be collected
from this region through the diffusion of ionized electrons and holes to the junction. This diffusion into the inbuilt 
electric field at the junction is the basis of passive mode operation of a P-I-N diode (i.e. no externally applied bias). 
The diode can be used as a dosimeter of ionizing radiation where the amount of charge collected is determined by 
the diffusion length of the minority charge carriers and/or the base length of the detector. Taking into account the 
energy required for the production of e-h (electron-hole) pairs in silicon is 3.6 eV, it is possible to show that the 
number of electron-hole pairs generated in silicon per cGy per cm3 is constant for silicon and equal to 4.2x1013
pairs/cGycm3. The current induced in the diode is proportional to the dose rate. Integration of the current gives the 
charge deposited which is proportional to the absorbed dose in silicon.
Understanding the physics behind the response of a diode in current mode is complicated and can be affected by 
dose rate, temperature, radiation defects and depends on the initial Si material and radiation treatment before use. 
Changing the dose rate of ionizing radiation affects the injection level and recombination properties of charge 
carriers in the base of the diode. Long term irradiation of the diode during use, either in phantom or in vivo, can lead 
to the accumulation of radiation defects and reduce the diffusion length of the charge carriers, ultimately reducing 
the sensitivity of the detector. A change in the temperature affects the level of recombination in the diode and 
ultimately the response. These performance affecting factors make the development of a good dosimetric diode quite 
a complicated task. Before any diode can be used, detailed characterization is required.
Many different approaches have been implemented to reduce the dose rate dependence of the diode: a reduction 
in the resistivity of the diode base, application of p-Si rather than n-Si, and pre-irradiation of the diode. In radiation 
therapy it is necessary to take into account that while the average dose rate during treatment is only about 200-400
cGy/min. The actual dose rate is of the order of 104 cGy/s due to the pulsed delivery from the medical LINAC. A 
more detailed analysis concerning the dose rate effects due to: initial parameters of the diode Si, pre-irradiation and 
fabrication technology can be found in [4,5].
The loss of sensitivity of a dosimetric diode due to radiation degradation depends on the energy of the incident 
radiation from the medical LINAC. The greater the energy the greater the degradation. To reduce this affect for p-
type diodes, the diodes can be irradiated prior to use or by reducing the initial life time of the charge carriers by 
doping the base of the diode. The typical loss in sensitivity of a commercial diode is 20-25% for an accumulated 
dose roughly greater than 10 kGy on electron and photon beams [6].
The variation in response of a diode due to temperature was observed to be in the range 0.02-0.28% per 0C for 
Scanditronics, Sun Nuclear and PTW diodes as reported in [5,7,8]. The variation depends on the prehistory of the 
diode and the initial material. This instability can affect the accuracy of the dosimetry, especially when the diode is 
placed on the body of the patient [8].
Diodes play an important role in radiation dosimetry. Single diodes can achieve a spatial resolution of about 1-
2mm and are well used in relative dosimetry for depth dose verification, beam profiling, as well as in vivo entrance 
and exit dose measurements. Dosimetry systems based on an array of single diodes have been built for 2D, and 
recently 3D, dose QA in IMRT and Volumetric Modulated Arc Therapy (VMAT). 2D diode arrays, for example 
MapCHECK has 445 Si diodes with 10 mm pitch, are useful for 2D relative dose mapping in a particular plane of 
the phantom perpendicular to central axis of each beam [9, 10, 11] and have proven themselves useful in IMRT QA. 
The pitch between diodes, usually 10mm outside and 5mm in the central part of the diode array, limits their spatial 
resolution in steep dose gradients, where often only one or two measurement points will be in the 20–80% penumbra 
region [10].  
Recently, several diode based dosimetry systems were developed for 3D dose plan verification in IMRT and 
VMAT. These devices have been fully characterized. The ScandiDos Delta4 (ScandiDose AB, Sweden) has bi-
planar orthogonal diode array planes with a total of 1069 p-Si diodes contained in a cylindrical phantom. This 
system allowed accurate QA of a complicated 3D dose plan delivery and provided absolute dosimetry on line 
[12,13,14].  Another system has been developed and tested. This ArcCHECK system has an isotropic arrangement 
of 124 diodes embedded in a cylindrical phantom (ArcCHECK, Sun Nuclear Corporation, Melbourne, FL) [15]. 
Both systems take into account temperature instability corrections of the diode, along with their angular and relative 
response variation via a quite complicated algorithm implemented to convert the real time response of the diode. 
This system has proven useful for pre treatment QA in IMRT. Details of the clinical applications of Delta4 can be 
found in this book [V.Feygelman et al.]
In spite of their small size most of commercial diodes cannot be used for surface dosimetry. This is due to the 
presence of packaging leading to a build up region that changes the depth of measurement. Fig 1 shows 3 typical 
dosimetric diodes, the packaging of each leads to a different build up characteristics when used in radiation therapy. 
Usually for 1-4 MeV photons the build up material is aluminium or copper, for 4-6 MeV photons brass is an option, 
and for 12-25 MeV photons tungsten is used. 
FIGURE 1 . Typical packaging of dosimetric diodes used in conventional therapy with different X-ray energies. (Reproduced
from [16]).
The diodes are intrinsically asymmetrical due to the sensitive region of each diode being surrounded by non 
uniform passive layers of silicon. These layers attenuate photons and produce electron backscattering with different 
characteristics than water. Additionally, the packaging of the diodes essentially determines their angular response; 
for more uniform angular response, high z-elements should be avoided in the diode packaging [17]. 
Single diodes and diode array detectors are one of the major and most convenient QA tools for relative and 
absolute dosimetry in radiation therapy. They have some limitations when high spatial resolution is required, and in 
particular the packaging and size of their sensitive volume can be an issue for skin dosimetry.
.
HIGH SPATIAL RESOLUTION SEMICONDUCTOR DOSIMETRY
High Spatial Resolution Dosimetry Using Diode Structures 
For high spatial resolution dosimetry, arrays of diode structures fabricated on silicon wafers like pixel or strip 
detectors, in addition to single diodes and single diode arrays, have been found very useful. They are convenient for 
multichannel readout using specially developed VLSI Application Specific Integrated Circuits (ASICS).
In Europe, the MAESTRO project (MAESTRO, 2008) proposed the development of pixelated Si detectors for 
high spatial resolution medical radiation dosimetry. The detector involved is a monolithic silicon segmented module 
[18]. Each pixel comprises of a p-n junction surrounded by a guard-ring structure implanted on an epitaxial 50 m
thick p-type Si layer grown on a Czochralski substrate. The sensitive area of each pixel is 2 × 2 mm2 with a 3 mm 
pitch. The first 441 pixels, 6.29x6.29 cm2 silicon module has been produced. This sensor has been connected to 
discrete readout electronics performing current integration and has been tested with satisfactory results. In the final 
configuration, nine silicon modules will be assembled together to cover an area close to 20x20 cm2 with 3969 
channels with ASIC readout electronics. This system has been shown to offer better resolution than most 
commercial 2D discrete diodes. 
The silicon strip detector is another position sensitive detector which is being developed by various groups for 
high spatial resolution medical radiation dosimetry. It is based on a planar array of p-n junction strips and widely 
used in high energy physics tracking detectors. Silicon strip detectors were used to characterize a Sr-90 intravascular 
brachytherapy source in terms of dose-depth curves in a tissue equivalent material, as well as the homogeneity of the 
source activity [19]. Another group has developed a 128 channel strip detector, the area of each strip being 0.25 × 
0.25 mm2 and pitch 0.3 mm, for stereotactic radiotherapy dosimetric verification [20]. Their work shows good 
agreement with a diamond detector for penumbra measurement applications [20,21].
Dose Magnifying Glass
Since 2003, the CMRP has been developing the concept of a high spatial resolution silicon dosimetry system 
with a large dynamic range (of the order of 103) for applications on medical linacs. The system is based on silicon 
strip detector technology. The Dose Magnifying Glass (DMG) is an array of 128 phosphor implanted n+ strips on a 
p-type silicon wafer (Fig 2). The sensitive area is defined by the dimensions of the n+ strip. DMGs with two 
different sensitive areas were designed: 0.02 × 5 mm2 and 0.02 × 2 mm2. The thickness of the Si wafers is 375 m
and the pitch of the strips is 200 m. Boron implanted p+ layers isolate the strips and prevent shorting of the n+ 
strips due to the ionizing radiation induced positive build up charge in the SiO2. Aluminum was evaporated on top of 
n+ areas, connected to Ni leads fanning out to two 68 channels connectors. The detector can be used in passive mode 
or biased mode and read out was carried out with the detector configured as a planar detector with a common p+ 
electrode on the same side as the n+ strips. Two types of device were produced, one with a resistivity of 5 kOhm·cm 
float zone silicon and the other with resistivity of 10 Ohm·cm Czochralski silicon.
FIGURE 2. DMG mounted on 0.12 mm thick kapton.
Tera VLSI ASIC Chip
The data acquisition (DAQ) system is an important issue in high spatial resolution real time dosimetry due to the
requirements for simultaneous readout of multiple channels (sensors). The readout electronics for the DMG uses two 
64 channel TERA VLSI ASIC chips that allow instantaneous readout of multiple channels. The TERA chip was 
designed by the Istituto Nazionale di Fisica Nucleare (INFN) - Torino Division and University of Torino 
microelectronics group working on the readout of pixelated ionization or strip chambers for hadron therapy
(http://totlxl.to.infn.it/NewSite/vlsi_chip.html, [22]). The ASIC is a current to frequency converter, followed by a 
16-bit counter. It has a dynamic range of  > 105 and is capable of measuring currents from a few pA to a few A
with a nonlinearity of less than 1%. The current to frequency conversion is based on the recycling integrator 
principle. The current is integrated via an operational transconductance amplifier (OTA). When the OTA output 
reaches a threshold level, the charge subtraction circuit is activated and the integrated current or charge is reduced by 
a fixed quantum charge, at the same time a pulse is issued to the counter. This charge subtraction method is far 
superior to the traditional resetting of the integrating capacitor, since the input current continues to integrate even 
during the charge subtraction. Hence, there is no dead time [23,24].
Various versions of the TERA family of ASICSs have been successfully implemented in the “Magic Cube
ionization chambers in hadron therapy [25-27] and in the gas ionization chamber based 2D planar array IMRT 
MatriXX and StarTrack (IBA Group, http://scanditronix-wellhofer.com/2D-verification.1458.0.html).
DMG Detector Characteristics
Silicon detectors have some disadvantages due to their dose rate dependence, angular dependence, energy 
dependence, and radiation damage susceptibility. However, with careful characterization, they are useful for relative 
dosimetric purposes. 
Similar to all Si detectors, the DMG is energy dependent and therefore sensitive to changes in the beam 
spectrum. The energy response of the DMG was studied for the energy range of 50kV to 10 MV nominal energies 
(corresponding to 26.8 keV – 2.97 MeV equivalent photon energies) [28]. The detector showed an enhanced 
response, up to six times, at lower photon energies with the maximum dose response at 75 kV nominal photon 
energy due to the increased photoelectric effect cross-section in silicon at low energies [29].
Due to the planer detector design as well as the ceramic substrate detector mounting, the maximum angular 
dependence of the DMG was 28.1% when the beam was incident parallel to the detector plane [28]. The 2nd 
generation of DMG, which was mounted on a 0.12 mm Kapton substrate, was able to improve the angular 
dependence by 12.8%. 
The dose rate dependence of the DMG is affected by the silicon resistivity and the pre irradiation conditions, 
much like a single silicon diode. The dose rate dependence can be reduced to 2% by using p-Si diodes made from 
low resistivity silicon, and by pre-irradiating the diodes to reduce the initial life time of charge carriers in the base 
material [5]. For the dose rate range of 200 – 840 cGy/min, the dose rate variation was < 5% for the unirradiated low 
resistivity device while for the pre irradiated device (irradiation with 15 kGy of 1 MeV electrons), the variation in 
dose rate response for the dose rate range of 80 – 600 cGy/min was < 2%. 
The linearity of the DMG for the dose range of 3.89 cGy to 311.05 cGy was excellent, while the depth dose 
measurement of a 6 MV photon beam shows good agreement with an ion chamber (within 0.8%) at all points up to 
20 cm depth [28] 
Application in Intensity Modulated Radiation Therapy
Intensity modulated radiation therapy (IMRT) is a complex mode of radiation delivery. It utilizes a multileaf 
collimator (MLC) to modulate the radiation beam to achieve dose escalation to the tumor while sparing the critical 
organs close to the irradiated target. IMRT plans tend to produce steep dose fall off regions at the interface of the 
target and organ-at-risk. The complexity of the IMRT delivery demands a far more rigorous quality assurance (QA) 
verification. In many facilities, patient based QA checks were carried out using ionization chambers for point dose 
measurements along with 2D or 3D diode or ion chamber arrays such as MapCHECK, IMRT MatriXX (IBA, 
http://scanditronix-wellhofer.com/2D-verification.1458.0.html) or Delta4 for fluence verification. These diode arrays 
are limited by their spatial resolution in high dose gradient regions [11,30]. IMRT dosimetric verification using the 
DMG is detailed in [28]. The benefit of 0.2 mm spatial resolution and the high temporal resolution measurement of 
the DMG was evident as it was able to capture the real time dose modulation for the IMRT delivery. Figs 3 and 4 
show the IMRT dose profiles for different gantry angles and the cumulative dose growth as measured by the DMG. 
FIGURE 3. IMRT dose measurement for different gantry angles. (Reproduced from [28]) .
FIGURE 4. Cumulative dose profile of an IMRT delivery. (Reproduced from [28]).
Application in stereotactic radiosurgery/radiotherapy (SRS/SRT)
Stereotactic radiosurgery (SRS) is the use of radiation to ablate a small lesion (usually < 4 cm in diameter) in the 
body. The treatment is normally delivered in a single large dose, resembling a surgery, hence the name. In some 
cases, the treatment is delivered in several smaller fractions; this is usually called stereotactic radiotherapy (SRT). 
The delivery of this treatment requires the use of stereotactic frames for precise target localization. This treatment 
delivery requires a tight margin with sharp dose fall off [31]. Hence, its quality assurance QA verification demands 
high geometric precision and accuracy. The challenge in SRT/SRS dosimetry is verifying the dose delivery with a 
trusted QA procedure in such a small field size. Dosimetry in small fields is susceptible to the problem of lateral 
electronic disequilibrium where more secondary electrons are generated by photons within the fields and scattered 
outwards, while less electrons are scattered into the field. On the other hand, the use of ion chambers or diodes with 
an active area that is comparable to the field size being measured (< 10mm) raises the issue of detector volume 
averaging that reduces the dose measured at the center of the beam, while artificially broadening the penumbra 
width. The clinical significance of this would be a systematic over-irradiation of the organ-at-risk arising from 
attempts to ensure sufficient PTV coverage during planning [20,32]. Insufficient spatial resolution of the detector 
that was used to collect the beam data during commissioning of the IMRT planning tool will produce error in the 
beam modeling of the treatment planning system, resulting in local discrepancies of > 10% between calculated cross 
profiles and profiles measured with films [33]. The authors also showed that the absolute dose difference was 
reduced to < 2% by simply using a detector with a smaller cross section, such as a 0.015 cm3 pin point ion chamber. 
Common techniques for SRS delivery are x-ray and gamma knife. For x-ray based SRS treatments, the treatments 
are carried out using a linear accelerator which delivers radiation to the target at iso-center with various non co-
planar arcs. However, in order to produce narrow beams for the small targets, tertiary collimators such as the micro 
multileaf collimator or cones are often used. DMG with the sensitive area of 0.02 × 2 mm2 is particularly useful for 
SRS QA and dosimetry. The DMG mounted on the end of a 0.12 mm kapton pigtail encapsulated in a solid water 
holder was used in conjunction with a custom made solid water head phantom. The phantom was screwed onto the 
commercial SRS couch mounting frame (fig. 5) [34]. This allows the DMG to measure non coplanar SRS treatment 
deliveries. One of the SRS QA procedures required prior to SRS delivery is the measurement of the center of 
rotation (COR) and position offset of the linac. The 0.2 mm spatial resolution capability of the DMG is comparable 
with the resolution of film dosimetry but with the added advantage of real time electronic readout. The COR of the 
linac gantry was determined from the center of the beam profiles obtained from the 0° and 180° gantry rotation. The 
COR offset is defined as half the difference between the x-coordinates of the two mid points of the beam profiles 
(fig. 6). The determination of the collimator and couch rotation was also determined in this manner. 
FIGURE 5. Experiment setup of DMG mounted in custom made SRS phantom for SRS treatment verification.
FIGURE 6. DMG used to measure the center of rotation offset. (Reproduced from [34]).
Application in helical tomotherapy
Helical tomotherapy is a radiotherapy treatment technique that is very different from the conventional linac. It 
resembles a diagnostic computed tomography (CT) machine in that it has a rotating gantry and it delivers radiation 
as the patient is translated through its bore. Similar to CT machine, it has an integrated imaging system comprising 
of 738 xenon filled ion chamber MVCT detectors sitting opposite the 6 MV linac, allowing the integration of image 
guidance and intensity modulated radiation therapy in a single system. Another feature that contrasted the helical 
tomotherapy with conventional linac is that the helical tomotherapy employs a binary multileaf collimator (MLC) 
instead of the conventional field shaping multileaf collimator to modulate the radiation [35,36]. The binary MLC is a 
64-leaf tungsten inter-digitated across the field. Modulation of the radiation is achieved by temporal modulation of 
the binary MLC as the linac rotates around within the gantry housing. This unique mechanism for dose modulation 
results in a unique dosimetric characteristic that is not present in a conventional IMRT delivery. New quality 
assurance procedures were devised to ensure the accuracy of the helical tomotherapy delivery [36-39]. Examples of 
helical tomotherapy specific QA procedures are: the MLC and gantry misalignment test, and leaf latency 
measurements. The MLC and gantry misalignment test is usually carried out during machine commissioning and 
after a new MLC bank is installed to ensure that the MLC misalignment is within the tolerance limit of  1 mm. The 
helical tomotherapy binary MLC can have only two states, open or closed. Due to the physical limitation of the 
mechanical and pneumatic system, a finite time is required for the leaf to change from a closed state to an open state 
and vice versa. This is known as the leaf latency. 
The use of the on board CT detector provides a convenient way of performing many of these QA procedures. 
Besides that, film is also one of the common dosimeters used for QA measurements. The DMG was proposed as an 
independent tool for performing some of the common QA procedures of helical tomotherapy [40]. Figure 7 shows 
the measurement of MLC misalignment using the DMG. For this measurement, the two central leaves (32 and 33) 
were opened and closed sequentially at a gantry angle of 0°. The gantry was then rotated to an angle of 180° and the 
same exposure was made. The double peak profile is the result of the tongue and grooves – penumbral effect of 
delivering the radiation by sequential opening and closing of the two adjacent leaves [39]. The MLC offset error was 
determined as half the distance between the mid points of the two profiles. The difference between the EDR2 film 
and DMG measurement was 0.16 mm, within the uncertainty of the measurements. Fig. 8 shows the leaf latency 
measurement of a tomotherapy leaf for the projection time of 50 ms to 303 ms. The leaf open time was programmed 
to open for a fraction of time and this is expressed as a percentage of the maximum projection time. 
The DMG was shown to be a suitable tool for providing machine independent QA checks in tomotherapy, with 
the capability to provide sub-millimeter resolution of any MLC misalignment and real time high temporal resolution 
measurements of leaf latency. 
FIGURE 7. MLC misalignment measurement using DMG. (Courtesy J.Wong et al [40]).
FIGURE 8. Helical tomotherapy leaf latency measurement for 50 ms, 100 ms, 200 ms and 303 ms projection. The leaf open time 
is expressed as percentage of the maximum leaf open time, i.e. a 50% of a 200 ms projection is 100 ms.(Courtesy J.Wong et al.
[40])
MOSFET DOSIMETRY
The application of MOSFET detectors to radiation therapy dosimetry is relatively new in comparison to 
conventional diode detectors. Actually, the application of MOSFET detectors to dosimetry was originally proposed 
for monitoring of space radiation doses to predict integral dose effects for electronics on satellites [41]. 
The main idea behind the operation of the MOSFET detector is the changing of the threshold voltage, Vth, which 
is the voltage on the gate of the MOSFET relative to the source. The change in Vth is due to the buildup in charge 
produced by ionizing radiation in the gate oxide, mostly at a Si-SiO2 interface. Fig. 9 shows the principal of 
operation of the MOSFET detector.
FIGURE 9. Schematic of an n-type MOSFET detector. Buildup charge in the gate oxide is produced by ionizing radiation.
Accumulated charge in the gate oxide is quite stable at room temperature. MOSFET detectors also exhibit only a 
small degree of fading (the deterioration of the signal over time), however, this depends on the oxide growing and 
annealing technology used during manufacturing. In these perspectives, the features of the MOSFET are similar to 
TLD detectors, allowing for readout of the MOSFET detector some time after irradiation with minimal deterioration 
of information. The sensitivity of the MOSFET detector is proportional to tox2, where tox is the gate oxide thickness. 
More detailed information on the fundamental physics and response of the MOSFET and RADFET detector to 
photon, electron and charged particle fields can be found in [42-45]. There are many advantages of MOSFET 
detectors in dosimetry applications, such as the extremely small size of the dosimetric volume (the gate oxide has a 
thickness of less than 1 micron, which is currently not feasible with other radiation detector technologies) dose rate 
independence, the possibility to compensate temperature instability of Vth by using a built in thermometer, which is 
the p-n junction as a part of the MOSFET, real time readout during treatment delivery in radiation therapy [46-48]
and the possibility of sensitivity adjustment by alteration of the gate bias during irradiation [43, 49]. MOSFET 
detectors produced in the same batch show reproducible results, with a spread in sensitivity within 1% [48]. This 
property makes them attractive for disposable applications, utilizing a “one dose” principle [50].
All of the above mentioned advantages of the MOSFET detector make them useful for dosimetry in locations of 
strong electronic disequilibrium. Such sites include the surface of the body, or anatomical cavities, and in buildup 
regions of MV X-ray beams. Thus, MOSFETs are suitable for dosimetry measurements in fields exhibiting a steep 
dose gradient, where the volumetric effect experienced by ionization chambers results in unreliable measurements. 
There are currently two MOSFET dosimetry systems offered on the commercial market. These are produced by 
Best Medical Canada Ltd. (Ottawa, Ontario, Canada) and Sicel Technologies (Morrisville, NC, USA) which produce 
the OneDoseTM system. An extensive bibliography on clinical applications of commercial MOSFET dosimetry 
systems in diagnostic and therapeutic radiation fields can be found in [http://www.mosfet.ca/publications/index.htm]
The Centre for Medical Radiation Physics (CMRP), University of Wollongong, is a developer of clinical 
MOSFET dosimetry systems. The Centre has obtained extensive experience with MOSFET dosimetry applications 
in a range of different radiation oncology modalities including medical LINACs [51-55], brachytherapy [56,57], 
microbeam radiation therapy [46,58-61] and neutron therapy [62-64]. A summary of the advantages and challenges 
of MOSFET dosimetry in a range of radiation therapy modalities has been presented in [2]. In the current review 
article we would like to demonstrate the further progress and advantages of MOSFET dosimetry, and in particular 
the new MOSkinTM detectors developed at the CMRP. The new MOSkinTM detectors are capable of measuring skin 
doses, which ICRP 1975 recommends be measured at a depth of 0.07 mm [65].  
Theoretically, the dose deposited at the surface (surface dose) and in the buildup region (entrance dose) of photon 
fields has two main contributors [66]. One is in-phantom scatter, due to photon interactions with the phantom 
material and subsequent generation of secondary electrons, which deposit energy along their path. The second is 
electron contamination, which derives from electrons produced outside the phantom striking the phantom surface, 
e.g. through photon interactions in the LINAC head. 
In practice, in vivo surface dose measurements represent a significant technical challenge as the epidermal layer 
of the skin is only 0.07 mm thick, approximately, and the radiosensitive basal layer lies at this depth [65]. The 
challenge of skin dose monitoring exists in breast cancer treatments, head and neck IMRT delivery and on the 
surface of the rectum wall during prostate cancer treatment, among others.
Similar to diode detectors, the response of MOSFET detectors depends on packaging technology. Most 
manufacturers place the MOSFET chip on a KAPTON film or thin printed circuit board carrier to which the 
MOSFET is wire bonded. An epoxy bubble is then placed on the top of the MOSFET chip for protection. For the 
MOSFET from Best Medical, the chip is mounted on a KAPTON carrier and covered by approximately 1 mm of 
epoxy coating. The equivalent depth in water for TN MOSFET sensors is 0.8 mm and 1.8 mm for the flat-sided and 
round-sided dosimeters, respectively, on the epoxy bubble side. This corresponds to percentage depth doses of 
35.6% and 56.1%, respectively, in relation to dose at Dmax for a 10 × 10 cm2 field of 6MV X-rays [67] instead of 
16% when measured by Attix parallel plate IC. A similar packaging effect with a RADFET chip consisting of 0.2 
mm printed circuit board carrier, covered with a 0.3 mm epoxy bulb (REM Oxford Ltd.), was observed in surface 
dose measurements in a hemi-cylindrical solid water breast phantom of 7.5 cm radius irradiated with 6 MV X-rays
when compared with GaF Chromic film measurements [51]. 
The MOSkinTM detector utilizes different chip packaging technology. Here, the protective epoxy bubble is 
replaced by a thin polyamide film. The design is presented in Fig. 10.
a) b)
FFIGURE 10. Comparison of the packaging between a typical MOSFET detector (a), and a MOSkinTM detector (b).
The MOSkinTM detector utilizes “drop in” technology, where a buildup polyamide film with thin Al leads has a 
reproducible water equivalent depth (WED) of 0.07 mm. The film is used for both electrical connection of the 
MOSFET chip to the KAPTON pigtail and chip protection. In such a design, the MOSFET chip is embedded in a 
0.35 mm thick KAPTON pigtail and protected from the environment with polyamide film on both sides. Fig 11 
shows a MOSkinTM probe. 
FIGURE 11. CMRP MOSkinTM probe. The pigtail is 40 cm in length, with drop in MOSkinTM detector at the end.
Fig. 12 shows a comparison of the response of the MOSkinTM detector placed “face up” on the surface of a solid 
water phantom (gate oxide facing the incident beam) irradiated with a 6 MV X-ray field from a medical LINAC. 
Curves are shown for 10×10, 5×5 and 2.5×2.5 cm2 field sizes and 100 cm focus-to-surface distance (FSD). 
Measured doses are presented relative to the dose at Dmax. The three solid curves in Fig. 12 represent percentage 
depth dose (PDD) curves produced by Monte Carlo simulations at CMRP, and are presented on a semi-log scale. 
The response of the MOSkinTM detectors correspond to doses measured at a WED of 0.07 mm for all three radiation 
fields.
FIGURE 12. Response of the MOSkinTM dosimeters on the surface of a solid water phantom in comparison to Monte Carlo 
PDD simulations. This demonstrates that the WED of measurements with the MOSkinTM is 0.07mm.
Fig. 13 shows the change in Vth for six randomly selected MOSkinTM detectors from the same batch following
irradiation with up to 10 Gy [48]. The response of the six MOSkinTM detectors was uniform over the 0-10 Gy dose 
range. For the MOSkinTM detectors used in this study, the calibration factor (CF) was 2.64 mV/cGy and the response
linear with R2 = 0.99994. These measurements were performed under a +15V gate bias during irradiation, using a
real-time computerized CMRP MOSFET reader.
FIGURE 13. Change in Vth for six MOSkinTM detectors for doses up to 10 Gy. A linear trend line has been fitted for guidance.
The linear response of the MOSkinTM detectors makes them ideal for disposable applications, such as in vivo skin 
and surface dosimetry after each or several fractions of radiation delivery, at sites with electronic disequilibrium. 
Examples of the attractive applications of the MOSkinTM include real-time dosimetry on the surface of the rectal wall 
during HDR brachytherapy and IMRT for prostate cancer and head and neck treatments.
A study was carried out to compare predicted and MOSkinTM measured surface doses during IMRT delivery for a 
head and neck treatment [68]. A specially designed MOSkinTM detector was placed on the interface between the oral 
plate and tongue during CT-simulation and treatment. The detectors were identified on the patient CT images and 
calculated point doses recorded during the treatment planning process. The measured doses were recorded in real-
time during treatment delivery. Fig. 14 shows the Corvus (Best Nomos, Pittsburgh, PA, USA) IMRT treatment plan 
with the MOSkinTM detector clearly identifiable on the sagittal CT images. Fig. 15 illustrates an example of the Vth
change, measured in real-time over 30 seconds with readout each second. The figure shows a) integral dose mode 
and b) dose increment mode. This clearly demonstrates the ability of the MOSkinTM to measure small dose 
increments (1-5) cGy and the pattern associated with MLC leaf motion during IMRT [69]. Results demonstrated that 
the individual patient variation of IMRT delivery to the tongue was less than 5% over the course of treatment, 
illustrating the in vivo application of the MOSkinTM to dose verification.
FIGURE 14. Example of Corvus IMRT treatment plan. The MOSkinTM detector can be identified on the patient CT images as 
shown by the white arrow.
a)
b)
FIGURE 15. A sample IMRT measurement of in vivo doses on the tongue during a single treatment fraction for nasopharyngeal 
carcinoma using real time MOSFET dosimetry system. a) accumulated dose variation; b) dose increment variation.
The CMRP MOSkinTM detectors were also applied to IMRT in vivo skin dosimetry for nasopharyngeal 
carcinoma (NPC) patients [47]. Several MOSkinTM detectors were placed on the head surface as radio-opaque 
markers during CT scanning. These MOSFETs were identified in the treatment planning system (TPS) and the 
calculated doses delivered to the detectors recorded. The dose difference between the MOSkinTM measurements and 
TPS calculations was on the average of -7.2% ± 1.2%, ranging from -4.3% to -9.2%. This reveals that attention 
should be paid to the skin dose calculations in the TPS system which overestimated dose at these superficial sites.
Other authors have reported similar results using film dosimetry [70], however the unique advantage of the
MOSkinTM lies in its ability to provide real-time surface dosimetry.
The application of MOSkinTM detectors to HDR brachytherapy has also been investigated. A custom made 
phantom containing special catheters for Ir-192 source dwelling was created to simulate the treatment of NPC. 
Dosimetry measurements with the MOSkinTM demonstrated good agreement with a specially created CT based 
treatment QA plan [57]. The percentage deviations between the measured doses and the planned doses were below 
5% for all the measurements at different orthogonal distances of the MOSkinTM from source train. The advantage of 
the MOSkinTM probe design in comparison with the epoxy bubble based MOSFET package was reflected in the 
reduced energy dependence of the MOSFET sensitivity with distance from the Ir-192 source. Changing the distance 
to the source from 1 to 5 cm resulted in a change in sensitivity of the MOSkinTM within 7% while a corresponding 
change of 24% was observed for a bubble based MOSFET (RADFET). This is associated with the dose 
enhancement due to the additional epoxy buildup, which has a higher atomic number than water [70]. 
MOSkinTM probes have been used to measure the dose from an Ir-192 HDR brachytherapy source along an empty 
air cavity in a phantom, simulating an empty rectum [71]. When placed along the wall of the empty rectal phantom, 
the dose measured by the MOSkinTM on the anterior rectal wall was 15.3% lower than the dose measured in a full 
rectal cavity at the same point. This was corroborated by the results obtained through a Monte Carlo GEANT4 
simulation, showing that the dose deposited along the anterior rectal wall of the empty cavity was 16.2% lower than 
in a full cavity. This demonstrates the usefulness of MOSkinTM detectors for surface dosimetry on the rectal wall in 
HDR brachytherapy.
The response of the MOSkinTM, as with all MOSFET detectors, is asymmetric by nature. This is due to the 
sensitive volume being located on a silicon slab, resulting in a non-uniform angular response. The design of the 
MOSkinTM probe mentioned above utilizes two MOSkinTM detectors in a face-to-face orientation, which has been 
dubbed the dual MOSkinTM. This leads to a symmetrical structure because the sensitive volume of each MOSkinTM is 
sandwiched between two silicon substrates and covered with 0.14 mm WED polyamide films. The response of the 
dual MOSkinTM is the sum of responses of both detectors. It was demonstrated that the angular response of the dual 
MOSkinTM is flat within ± 2.5% for the azimuth axis and -2.5% and +4% for the polar axis [48]. 
The dual MOSkinTM was applied to point dosimetry on the anterior rectal wall in external beam radiotherapy, in 
conjunction with an endorectal balloon used for immobilization of the prostate (see Fig. 16). In vivo dosimetry of 
the rectal wall is an appealing method for verification of target and organ at risk (OAR) doses. An in vivo dosimeter 
placed on the anterior rectal wall would allow the clinician to measure the dose delivered to the section of the rectum 
receiving the highest dose. This is important, particularly for recent hypofractionation schedules, where high doses 
are delivered to the prostate and anterior rectal wall, and would be particularly useful in the context of the limitations 
of dose calculation algorithms at cavity interfaces. Additionally, accurate knowledge of the anterior rectal wall dose 
is necessary for correlation of delivered dose to rectal toxicity. A secondary application of an in vivo anterior rectal 
wall dosimeter would be for target dose verification. The anterior rectal wall is generally contained by the Planning 
Target Volume (PTV) and therefore any dosimeter placed on the anterior rectal wall can be used as a surrogate for 
the PTV dose at the posterior region of the volume [48].
FIGURE 16. The dual MOSkinTM detectors placed in the outer lumen of the RadiaDyne (Houston, TX, USA) rectal balloon
(Reproduce from [48]).
The rectal balloon with dual MOSkinTM detector was placed in a specially designed solid water phantom. A
planning CT scan was taken of the phantom set up. The CT data was transferred to the Pinnacle treatment planning 
system (TPS) (Philips Medical Systems, Middleton, WI, USA) where contours of a hypothetical prostate, rectum 
(the balloon cavity), bladder and femoral heads were created. 3D conformal radiation therapy (CRT) and IMRT 
plans were created in the Pinnacle TPS. The dual MOSkinTM was visible on the CT scan and the planned dose to the 
detector was recorded for both treatment plans. Fig. 17 shows the real-time measured anterior rectal wall dose for (a) 
3D CRT 7 field plan and (b) single fraction of an IMRT plan. The error bars are the 95% confidence interval of the 
average of three measurements.
FIGURE 17. Real-time measured anterior rectal wall dose for (a) 3DCRT plan and (b) IMRT plan (Reproduce from [48]).
The difference in dose patterns between a) and b) is related to MLC leaf movement and is clearly reflected in the 
real-time MOSkinTM measurements. Measured and planned integral doses were in close agreement, confirming again 
that the MOSkinTM detector is a useful tool for real-time in vivo treatment delivery verification. More details can be 
found in [48].
The temperature dependence of the MOSkinTM detector response, Vth(T), is an important factor for in vivo 
dosimetry. This is particularly so when the temperature of the detector can change during the time between initial 
readout and readout after irradiation. This temperature dependence is dictated by the temperature dependence of the 
concentration and mobility of the charge carriers in the gate channel.
0.9
0.95
1
1.05
1.1
15 20 25 30 35 40
Temperature (C)
R
el
at
iv
e 
vo
lta
ge
 c
ha
ng
e
FIGURE 18. Temperature dependence of the response of the MOSFET detector irradiated under different temperatures. Picture 
is courtesy of M.Butson, ICCC, Australia.
Fig. 18 shows the relative dependence of the p-MOSFET (REM Oxford Ltd.) response when irradiated at
different temperatures. The range of temperatures corresponded to that encountered for in vivo clinical conditions. 
The data was obtained with the CMRP MOSFET dosimetry system and presented in [72]. Similar results were 
demonstrated for an n-MOSFET over a temperature range of (-60 to +60)oC [43]. The results demonstrate the 
temperature independence of sensitivity of the MOSFET detectors for clinically relevant temperatures. Thus, only a
single calibration coefficient is required and changes in ambient temperature can be neglected when initial and final 
readout has been performed at the same temperature. If the latter does not hold, a temperature correction of Vth must 
be implemented or MOSFET should have built is temperature instability correction like mentioned above. For 
example, In the Best Medical MOSFET dosimetry systems, the dual MOSFET approach has been used to 
compensate for temperature instability of the threshold voltage [49].
SEMICONDUCTOR DOSIMETRY FOR DOSE EQUIVALENT IN CHARGED 
PARTICLE THERAPY
Microdosimetry
In conventional radiation therapy with electrons and photons, the absorbed dose and fractionation schedule are 
sufficient parameters for predicting tumor control. In charged particle therapy, neutron and binary therapies 
additional knowledge of the Radiobiological Efficiency (RBE) is important. In most of these therapies the RBE > 1 
and in charged particle therapy is changing along the Bragg Peak (BP) or spread out Brag Peak (SOBP) due to a 
change in the LET of charged particles and the production of high LET products due to inelastic reactions. Charged 
particle therapy (proton and heavy ion) is very conformal and the discrete range of particles can be advantageous in 
sparing normal tissue. It is however accompanied by the production of neutrons in out-of-field areas that can lead to 
a risk in the production of second cancers. An estimation of the dose equivalent rather than absorbed dose is another 
important task of radiation dosimetry. The microdosimetry technique is based on a measure of the stochastic energy 
deposition events that occur on a cellular level, this is in contrast to the deterministic effect described by absorbed 
dose, and can be used for estimating the dose equivalent and RBE of therapeutic and mixed radiation fields. A 
detailed description of the microdosimetric approach and associated formalisms can be found in [73]
Semiconductor microdosimetry based on the representation of biological cells with an array of micron sized 
semiconductor sensitive volumes was introduced by us and described in [73, 74] and the references contained there. 
In this paper the further progress on SOI semiconductor microdosimetry and examples of its application for dose 
equivalent and quality factor Q measurements in proton therapy is presented in brief. 
The first generation of SOI microdosimeters was based on an array of adjacent right angular 30x30x10 m3
reverse biased p-n junctions (SVs). Shortcomings of this microdosimeter were the poorly defined charge collection 
volume and the localization of a single SV in comparison with a Tissue Equivalent Proportional Counter (TEPC) 
[75,76]. A new SV design has been proposed (see Fig. 19). This design aims to realize a 3D p-i-n diode with a well-
defined cylindrical sensitive volume frequently used in TEPC. With this geometry, a better chord length variance is 
obtained when compared to an elongated rectangular geometry. A cylindrical volume supports a 1/r electrical field 
distribution which facilitates the collection of all deposited charge. Better localization of the SV outside of 
neighboring SVs has been achieved by the fabrication of mesa structures on SOI. A schematic of the new SV 
structure is shown in Figs. 20 (a) and (b). Fig 20 (c) shows array of mesa cylindrical SVs and a scanning electron 
microscope picture of a single mesa with connections. The fragment on Fig 20 (c) shows the way SVs are connected 
such that each SV is surrounded by another 4. Odd and even SVs are read out separately to realize the concept of 
regional microdosimetry in solid state microdosimetry. More details on the design of the second generation of SOI 
microdosimeters and their characterization can be found in [77-79]. The conversion of the silicon cylindrical SV 
geometry to water equivalent geometry can be achieved by simple scaling [80]. From this water or tissue equivalent 
microdosimetric spectra y2f(y) vs y can be found and finally the dose equivalent by combining the spectra with the 
defined ICRP quality factor Q(y) [73]. 
FIGURE 19. A schematic of the new 2nd Generation SOI SV (Reproduced from [78]).
FIGURE 20. (a) Schematic top view of the cylindrical SV of SOI microdosimeter. (b) Schematic cross section of the cylindrical 
SV of SOI microdosimeter. (c) The microdosimeter array consists of array of cylindrical diodes. Individual diodes are connected 
odd-evenly in such a way that any single odd connected diode is surrounded by 4 identical even connected diodes.(d) electronic 
microscope picture of array of mesa SVs and single mesa SV as on a (b). (Reproduced from [78]).
In radiation therapy SOI microdosimetry has been applied to measure the dose equivalent outside of a primary 
proton beam. Both neutrons and scattered protons contribute to the dose equivalent in these regions. Passive beam 
delivery techniques provide a source of secondary neutrons due to the presence of beam modification devices such 
as scattering foils, modulator, aperture, and bolus [81]. Downstream of the Bragg peak the contribution to dose 
equivalent is from neutrons only. Active delivery techniques produce less neutrons out-of-field in comparison with 
passive delivery as has been demonstrated by Monte Carlo studies [82, 83]. Dose equivalents out-of-field using SOI 
microdosimeters were measured within a polystyrene phantom for different clinical scenarios at the Loma Linda 
University Medical Centre (LLUMC) and Massachusetts General Hospital (MGH) proton therapy facilities [84, 85]. 
Fig. 21 shows external field dose-equivalent and average quality factor values as a function of depth along the 
direction of the primary beam. The detector is situated at the height of the beam central axis for a patient-specific 
prostate configuration at a distance 5 cm from the field edge and for the solid brass beam block on the beam central 
axis. For the beam block, dose equivalent decreased from an initial value of 7.1 mSv/Gy at the phantom surface to 
SiO2
i-Si
Al
w
Contact 
d
P+ P+N+
i-Si
AlSiO2
t
w
Si substrate
Buried oxide
(a)
(b)
ODD
GND
GND
(c)
EVEN ODD
ODDEVEN
EVEN
EVEN
EVEN
ODD
ODD
ODD
(d)
d
Al
0.5 mSv/Gy at a depth of 33.5 cm. For the patient-specific configuration, dose equivalent decreased from an initial 
value of 5.5 to 2.4 mSv/Gy at 22.5-cm water equivalent depth (WED) normalized to 1 Gy absorbed dose delivered at 
the centre of the SOBP. 
b)
FIGURE 21. Dose equivalent (a) and average quality factor (b) distributions as a function of depth within a homogeneous 
plexiglass phantom. Measurements completed using a patient specific aperture and bolus combination at 5cm from the field edge, 
and a solid brass beam block along the central axis. (Reproduced from [85]).
The average quality factor increased from 3 to 5 within the SOBP region of the patient specific treatment, while a 
decreasing quality factor was observed in the case of the beam block. This is because with depth the contribution to 
lateral dose equivalent is mostly from neutrons rather than high energy scattered protons. These neutrons are 
generating recoil protons with a higher LET than scattered protons. This is in good agreement with the quality factor 
along the central axis for the beam block and downstream of the SOBP where only neutrons are presented. More 
detailed information on the dose equivalent and Q-factors measured by SOI microdosimeters in out-of-field proton 
therapy can be found in [84,85]. An advantage of SOI microdosimetry is the small physical size of the detector SV 
in comparison with most TEPC and Bonner spheres. This allows measurement at points of interest close to the field 
edge and immediately behind the SOBP where critical organs may be located in many proton therapy scenarios.
E-E Silicon Detectors in Proton Therapy dosimetry.
Monolithic silicon E-E detectors have been found useful for dosimetry in proton therapy. Compared to a 
classical microdosimeter which provides one-dimensional information on the lineal energy spectra of primary and 
secondary charged particles, this detector system provides two-dimensional information on lineal energy and particle 
energy based on energy depositions collected in coincidence within the E and E stages of the detector. This 
provides a unique signature for secondary or direct charged particles on a E-E scatter plot.
A biological matrix can be formed by assigning each pixel on the scatter plot a RBE() value derived from V79 
in vitro cell survival data in the low dose limit. The average RBE() can be presented as :
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where Ni,j is the frequency of events for the cell Ei , (E+E)j and Ei,j is the energy deposited within the E-E 
telescope for the cell Ei , (E+E)j. The resultant quantity RBE() is thus the dose-weighted average RBE in the 
low-dose limit for a given measured radiation field that is governed by the RBE() values used in the conversion 
matrix. This proposed approach to determining RBE in charged particle therapy is in addition to the classical 
regional microdosimetry approach linking experimental cell radiobiology closely to the detector response rather than 
only through the quality coefficient Q(y). This attempt is taking into account the track structure of the ion, i.e. two 
particles with the same Z2/V2 (Z- is a charge and V is a speed of particle) will have the same LET or lineal energy 
but will present at different locations on a E-E scatter plot and as result possess different  RBE().
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Fig. 22. shows a schematic of the E-E monolithic detector which was developed by ST Microelectronics and 
Milano Polytechnic and has previously been described in detail [86]. In the E-E detector a buried p+ layer was 
achieved via 2 MeV B implantation into the bulk of n- silicon. The detector had an effective surface area of 1x1 
mm2. During experiment the detector was housed in a specially designed PMMA probe within a PMMA phantom 
and irradiated with a 100 MeV proton beam. A custom made data aquistion system was used in read out. The probe 
was placed at different depths along the central axis of a pristine and SOBP as described in [87]. Fig. 23 shows an 
example of a E-E scatter plot obtained at a depth of 7.5 cm corresponding to the distal edge of the 100 MeV proton 
Bragg peak. Fig 24 shows the RBE() matrix derived from published  data on V79 cell survival data [87,88].
FIGURE 23. -E scatter plot at depth 7.5cm [88]
FIGURE 24.  !
	". (Reproduced from [88]).
Fig 25 and 26 show the absorbed dose as measured by an ionization chamber in the PMMA phantom and the 
average RBE () change along the pristine and SOBP [87,88]. 
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The increase in RBE along the BP or SOBP was experimentally observed. The high spatial resolution of the 
detector made measurements possible, making it valuable for phantom measurements and QA applications in hadron 
therapy treatment planning. The difference in RBE () downstream of the BP and SOBP respectively may be 
attributed to the different neutron spectra present at the corresponding points due to the modulation wheel used to 
generate the SOBP. 
As this method is based on actual radiobiological data, it can potentially be refined by including other in vitro 
and in vivo data for a range of cell lines, tissues, and clinical end points. Recently a monolithic E-E detector was 
used for identifying the fragments produced on a 62 MeV/u 12C ion beam [8]. With a range in PMMA of only 8 mm 
the spatial resolution of the E-E detector was essential; measurements with a TEPC would not have been possible.
An advantage of semiconductor detectors for RBE and dose equivalent measurements in charged particle 
radiation therapy is their high spatial resolution. Measurements close to the field edge or at positions and detailed 
dosimetry along the BP and SOBP are easily obtained and would otherwise be impossible with a TEPC.   
CONCLUSION
In this paper, current developments in semiconductor radiation detector technology for radiation therapy 
dosimetry and QA was presented. Silicon remains the main element of most clinical semiconductor dosimeters. The 
design of the single diode is continuing to improve. Passive diodes have been designed that allow charge collection 
from the total bulk volume, and consideration is being made into the packaging of single diodes to reduce the 
angular response and create effective detector depths relevant for skin dosimetry. For better phantom dosimetry on 
modern medical LINACs, sophisticated diode array dosimeters are being used. The recently developed ScandiDos
Delta4 (ScandiDose AB, Sweden), with two orthogonal diode array planes contained in a cylindrical phantom, and 
ArcCHECK, (Sun Nuclear Corporation, Melbourne, FL) with an isotropic arrangement of diodes embedded in a 
cylindrical phantom, combined with advanced read out algorithms allow comprehensive 3D dose verification QA in 
IMRT and VMAT. 
A new trend in semiconductor dosimetry for QA involves multiple diode detectors on a silicon substrate, each 
read out individually using a specially designed multichannel ASIC. Such dosimeters allow high spatial resolution to 
be achieved. The Dose Magnifying Glass consists of a number of silicon strip detectors, it has high temporal 
resolution and provides a spatial resolution of 0.2mm which is otherwise impossible using a single diode array. The 
DMG provides a unique and important option for small field / real time phantom QA in SRS, IMRT and 
tomotherapy. It provides dosimetry options not possible using other detectors, including the EPID.   
The MOSFET detector has been successfully used as a dosimeter in the clinic for over a decade. A recent 
advance in the MOSFET for clinical dosimetry is the MOSkinTM . This detector utilizes special packaging 
technology that allows for reproducible skin dosimetry at a WED of 0.07 mm. MOSkinTM detectors are used for in 
phantom QA, real time in vivo skin dosimetry of breast cancer patients, IMRT for NCP patients and can be placed 
on a rectal balloon for rectal wall dosimetry in prostate treatments. New packaging of MOSkinTM detectors reduce 
the energy dependence of the detector response in comparison with the conventional epoxy bubble packed MOSFET 
detector and make the MOSkinTM more suitable for HDR brachytherapy dosimetry. An important feature of this 
detector probe is that it is not affected by magnetic fields, making it suitable for real time QA in MRI guided 
radiotherapy.
Further development has been in integrated silicon dosimetry utilizing pixelated detectors. These detectors have a 
high spatial resolution and can be used for derivation of the relative RBE along the SOBP and in out-of-field 
regions. SOI microdosimeters with micron sized cylindrical sensitive volumes that better match a TEPC were 
developed and investigated. The SOI microdosimeter has been successfully used for dose equivalent measurements 
in out-of -field regions in proton therapy. A comparison of dose equivalent measures and associated risk of second 
cancer for different clinical scenarios was achieved. A new generation of microdosimeters will be produced based on 
Micro Electronic Mechanical Systems (MEMS) technology to produce micron sized free standing 3D cylindrical 
SVs with low capacitance [90].
Monolithic silicon E-E detectors have traditionally been used in nuclear research for particle identification; 
recent work has applied them to RBE() derivation in proton therapy. Measurements were made along the Bragg 
peak and combined with known radiobiological cell data. The proposed silicon integrated detectors can be used for 
out-of-field neutron dosimetry on medical LINACs similar to proton therapy. 
Further semiconductor clinical dosimetry has been in a progress which was not included in this paper.  The 
pixilated silicon detector MEDIPIX has been successfully used for fast 3D dosimetric imaging with spatial 
resolution 55 microns of eye plaques with I-125 seeds and Ru-106, details can be found in [91]. The advantage of 
microelectronics was recently realized in new miniature Si special diode detectors, allowing 5 m spatial resolution 
in real time dose verification for in-phantom QA on MRT beam array [92]. The progress in semiconductor detector 
technology clearly demonstrates the future such detectors have for QA in clinical dosimetry with high spatial 
resolution, real time dosimetric imaging possible.
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